SOURCE: IsoRay, Inc

IsoRay Makes First Cesium-131 Delivery for Treatment of an Inoperable Brain Cancer Afflicting a Young Child in Peru

IsoRay Raced to Deliver Cesium-131 Seeds to Treat a 7 Year Old Girl Who Was in Desperate Need of Treatment

IsoRay Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced the first Cesium-131 seed shipment to Peru for the treatment of a Glioma brain tumor located near the brainstem.

 

Dr. Carlos Alvarez, Neurosurgeon at Instituto de Columna y Cerebro in Lima, successfully completed the world's first stereotactic brain implant utilizing Cesium-131 seeds. Dr.Alvarez said "The patient was a 7 year old female who was diagnosed with a 3 centimeter inoperable Glioma brain tumor that was positioned close to the brainstem. Due to the size and tumor location, surgery and delivering high dose radiation using radiosurgery was not an attractive option." Following the procedure Dr. Alvarez reported that there were no postoperative complications and the young girl was awake with no additional neurological deficit.

 

IsoRay CEO Dwight Babcock stated "These cases pull on your heart strings and IsoRay's team rose again to the challenge in support of physicians worldwide and patients in need. By placing custom made Cesium-131 within the tumor, a very high dose can be delivered while sparing other critical structures in the brain and brainstem. IsoRay's ability to deliver our isotope required the timely cooperation of Peruvian governmental agencies and our distributor BioProPeru. Thankfully the early reports from Dr. Alvarez are very rewarding to those who worked so hard on this case and we hope for continued success. We are extremely pleased with the exceptional results a growing number of thought leaders and major medical centers are experiencing throughout the U.S. and internationally as Cesium-131 receives more widespread adoption. We believe Cesium-131's ability to fight cancer with new delivery options while improving the quality of life for the men, women, and children who are battling these devastating cancers distinguishes it from other treatment options."

 

IsoRay is the exclusive manufacturer of Cesium-131. The pioneering brachytherapy is one of the most significant advances in internal radiation therapy in 20 years. Cesium-131 allows for the precise treatment of many different cancers because of its unrivaled blend of high energy and its 9.7 day half-life (its unequaled speed in giving off therapeutic radiation).

 

In addition to its CMS codes, Cesium-131 is FDA-cleared and holds a CE mark for international sales in seed form for the treatment of brain cancer, prostate cancer, lung cancer, ocular melanoma cancer, colorectal cancer, gynecologic cancer, head and neck cancer and other cancers throughout the body. The treatment can be deployed using several delivery methods including single seed applicators, implantable strands and seed sutured mesh, and several implantable devices including the GliaSite® radiation therapy system, the world's only liquid radiation balloon catheter device used in the treatment of brain cancer. 

 

About IsoRay 

IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 by visiting www.isoray.com. 

 

Join us on Facebook/Isoray. Follow us on Twitter @Isoray.

 

Safe Harbor Statement 

Statements in this news release about IsoRay's future expectations, including: the advantages of our products and their various delivery formats, whether adoption of our products will continue to increase, whether IsoRay will be able to continue to expand its base beyond prostate cancer, whether treatment of brain cancers using Cesium-131 will be successful in this and future cases, whether future studies of treatment of various cancers using our products will have favorable results, and all other statements in this release, other than historical facts, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of our products, our ability to successfully manufacture, market and sell our products, our ability to manufacture our products in sufficient quantities to meet demand within required delivery time periods while meeting our quality control standards, our ability to enforce our intellectual property rights, whether ongoing patient results with our products are favorable and in line with the conclusions of clinical studies and initial patient results, patient results achieved when our products are used for the treatment of cancers and malignant diseases beyond prostate, whether additional studies are released and support the conclusions of past studies, whether we, our distributors and our customers will successfully obtain and maintain all required regulatory approvals and licenses to market, sell and use our products in its various forms, successful completion of future research and development activities, the success of our sales and marketing efforts, changes in reimbursement rates, changes in laws and regulations applicable to our products, and other risks detailed from time to time in IsoRay's reports filed with the SEC.

 

 

CONTACT:

 

IsoRay Medical

(509) 375-1202

Info@Isoray.com

Worldwide Financial

(954) 360-9998

info@wwfinancial.com

 

 

SOURCE: IsoRay, Inc.